Austin Fox, MD
Glaucoma Specialist · Irvine, CANPI 1851740591
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2023 at $3,822 and has fallen 91.8% since, to $312 in 2025.
Across 45 payments — averaging $139.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$1K
- NEW World Medical,inc.$1K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- AbbVie$461
- Glaukos Corporation$346
- plus $559 from 6 others
What the payments were for
- Consulting fees$2,53541%
- Speaking & faculty fees$1,20019%
- Food & beverage$2,51240%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $1,470 |
| NEW World Medical,inc. | 3 | $1,275 |
| Alcon | 15 | $1,077 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $1,067 |
| AbbVie | 11 | $461 |
| Glaukos Corporation | 5 | $346 |
| Amgen | 1 | $125 |
| Novartis | 1 | $124 |
| Astellas Pharma US Inc | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Sight Sciences, Inc. | 3 | $70 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$1,200
- Clearpath$1,200
- Ahmed Glaucoma Valve$1,200
- Streamline$1,200
- Tecnis Simplicity$1,065
- iStent inject W$164
- iStent Trabecular Micro-Bypass System Model iS3$130
- TEPEZZA$125
- Izervay$123
- XEN GLAUCOMA TREATMENT SYSTEM$105
How this compares
$6,255 in reported general payments places this provider in the 60th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 62 | $58,439 |
| RhopressaNetarsudil Mesylate | 98 | $38,156 |
| VyzultaLatanoprostene Bunod | 91 | $33,779 |
| CombiganBrimonidine Tartrate/Timolol | 90 | $30,800 |
| LumiganBimatoprost | 73 | $28,848 |
| XiidraLifitegrast | 19 | $28,021 |
| Cyclosporine | 68 | $20,656 |
| Alphagan PBrimonidine Tartrate | 54 | $19,274 |
| Brimonidine Tartrate | 579 | $13,508 |
| Latanoprost | 1,361 | $12,833 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 658 | $10,963 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $10,173 |
| AzoptBrinzolamide | 12 | $9,198 |
| XalatanLatanoprost | 15 | $7,556 |
| Travoprost | 39 | $6,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $461 | $137,361279 claims |
| AlconAzopt, Simbrinza | $1,077 | $14,68924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Irvine
- Sameh MosaedIrvine$44K
- Ken LinIrvine$30K
- Andrew SmithIrvine$4K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.